It is also not correct to discount other treatments by saying they don't have to demonstrate superior efficacy to them. The trial will need to show overall survival benefit. The patients will have the option before and after the trial (those surviving) to try other drugs which obviously effects survival rates.
It is also not correct to discount other treatments by saying...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.040(2.42%) |
Mkt cap ! $274.1M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.70 | $1.60 | $229.6K | 139.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 129 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 2839 | 1 |
View Market Depth
| Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |